Lentivi­ral vec­tor short­age looms un­less man­u­fac­tur­ing hur­dles from clin­i­cal to com­mer­cial are ad­dressed

With the an­tic­i­pa­tion that more gene ther­a­pies will en­ter the mar­ket, man­u­fac­tur­ers could strug­gle to meet de­mand if lentivi­ral vec­tor short­age risk is not tack­led, man­u­fac­tur­ing in­sid­ers told End­points News.

“The ma­jor­i­ty of the in­dus­try has fo­cused on a process [for lentivirus­es] that is not scal­able,” said Su­par­na Sanyal, Lon­za’s head of vi­ral vec­tor, com­mer­cial de­vel­op­ment, in an in­ter­view. “So there, the short­age is much more promi­nent,” she added.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER